Summit Therapeutics Inc. (SMMT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US86627T1088
Summit Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| EBIT | -1.08 bn USD |
| Net income | -1.08 bn USD |
| Diluted EPS – continuing operations | -1.44 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
More stocks
- Realtek Semiconductor Corp (2379.TW)
- Zhejiang Nhu Co Ltd (002001.SZ)
- Lingyi iTech Guangdong Co (002600.SZ)
- Mora Telematika Indonesia (MORA.JK)
- Smith & Nephew PLC (SN.L)
- CROWN HOLDINGS, INC. (CCK)
- McCormick & Company (MKC)
- Zhejiang Juhua Co Ltd (600160.SS)
- Sino Biopharmaceutical Ltd (1177.HK)
- Erie Indemnity (ERIE)
- Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301.SZ)
- Toll Brothers, Inc. (TOL)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.